Evidence map›Paper›PMID 24163065›Full record

ArticleCirculation2014

Vascular progenitors from cord blood-derived induced pluripotent stem cells possess augmented capacity for regenerating ischemic retinal vasculature.

Tea Soon Park, Imran Bhutto, Ludovic Zimmerlin, Jeffrey S Huo, Pratik Nagaria, Diana Miller, Abdul Jalil Rufaihah, Connie Talbot, Jack Aguilar, Rhonda Grebe and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Circulation, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed
4.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

53 citing papers in PubMed, 95 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Applications of synthetic biology in medical and pharmaceutical fields.Signal transduction and targeted therapy · 2023
    Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 5 institutions in 1 country.

Tea Soon ParkInstitute for Cell Engineering, and Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD (T.S.P., L.Z., J.S.H., J.A., E.T.Z.); Wilmer Ophthalmological Institute, Johns Hopkins University School of Medicine, Baltimore, MD (I.B., R.G., C.M., G.L.); Department of Radiation Oncology (P.N., F.R.) and Department of Microbiology/Immunology (D.M., R.A.F.), University of Maryland School of Medicine, Baltimore, MD; Department of Cardiovascular Medicine (A.J.R., J.C.) and Institute for Stem Cell Biology and Regenerative Medicine (A.J.R., R.R.-P., J.C.), Stanford University, Palo Alto, CA; and Institute for Basic Biomedical Science at Johns Hopkins School of Medicine, Baltimore, MD (C.T.).
Imran Bhutto
Ludovic Zimmerlin
Jeffrey S Huo
Pratik Nagaria
Diana Miller
Abdul Jalil Rufaihah
Connie Talbot
Jack Aguilar
Rhonda Grebe
Carol Merges
Renee Reijo-Pera
Ricardo A Feldman
Feyruz Rassool
John Cooke
Gerard Lutty
Elias T Zambidis
California Institute for Regenerative Medicine · USJohns Hopkins Medicine · USStanford University · USJohns Hopkins University · USUniversity of Maryland, Baltimore · US

Funding

LAB RESEARCH TRAINING IN PEDIATRIC ONCOLOGY-HEMATOLOGYT32CA060441 · NCI · JOHNS HOPKINS UNIVERSITY · PI ALAN D FRIEDMAN · 1993 to 2026
$14.9M
Basic and Translational Research of iPSC-Based hematologic and Vascular TherapiesU01HL099775 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI FRIEDMAN, ALAN D · 2009 to 2015
$8.4M
Basic and Translational Research iPSC-based hematologic and vascular therapiesU01HL100397 · NHLBI · STANFORD UNIVERSITY · PI COOKE, JOHN P · 2009 to 2015
$7.4M
METHYLATION OF THE CALCITONIN GENE IN HUMAN TUMORSR01CA043318 · NCI · JOHNS HOPKINS UNIVERSITY · PI BAYLIN, STEPHEN B. · 1986 to 2013
$6.0M
Vasculogenesis and hyperoxia in the developing retina.R01EY009357 · NEI · JOHNS HOPKINS UNIVERSITY · PI LUTTY, GERARD ANTHONY · 1993 to 2014
$5.3M
Pluripotent Stem Cell Vascular Therapies for Ischemic RetinopathiesR01EY023962 · NEI · JOHNS HOPKINS UNIVERSITY · PI ZAMBIDIS, ELIAS T. · 2014 to 2018
$1.8M
Origin of HSC from Embryonic Stem CellsK08HL077595 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI ZAMBIDIS, ELIAS T. · 2004 to 2008
$666k
Transcriptional and Epigenetic Regulation of HSC Generated from iPS and ESCR03HL096220 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI FRIEDMAN, ALAN D, ZAMBIDIS, ELIAS T. · 2009 to 2009
$41k
NCI NIH HHS CA60441NCI NIH HHS R01 CA043318NCI NIH HHS T32 CA060441NEI NIH HHS EY01761NEI NIH HHS R01 EY009357NEI NIH HHS R01 EY023962NEI NIH HHS R01-EY09357NHLBI NIH HHS K08 HL077595NHLBI NIH HHS R03 HL096220NHLBI NIH HHS U01 HL099775NHLBI NIH HHS U01HL099775NHLBI NIH HHS U01 HL100397NHLBI NIH HHS U01HL100397
6 · The paper itself

Abstract

backgroundThe generation of vascular progenitors (VPs) from human induced pluripotent stem cells (hiPSCs) has great potential for treating vascular disorders such as ischemic retinopathies. However, long-term in vivo engraftment of hiPSC-derived VPs into the retina has not yet been reported. This goal may be limited by the low differentiation yield, greater senescence, and poor proliferation of hiPSC-derived vascular cells. To evaluate the potential of hiPSCs for treating ischemic retinopathies, we generated VPs from a repertoire of viral-integrated and nonintegrated fibroblast and cord blood (CB)-derived hiPSC lines and tested their capacity for homing and engrafting into murine retina in an ischemia-reperfusion model. METHODS AND

resultsVPs from human embryonic stem cells and hiPSCs were generated with an optimized vascular differentiation system. Fluorescence-activated cell sorting purification of human embryoid body cells differentially expressing endothelial/pericytic markers identified a CD31(+)CD146(+) VP population with high vascular potency. Episomal CB-induced pluripotent stem cells (iPSCs) generated these VPs with higher efficiencies than fibroblast-iPSC. Moreover, in contrast to fibroblast-iPSC-VPs, CB-iPSC-VPs maintained expression signatures more comparable to human embryonic stem cell VPs, expressed higher levels of immature vascular markers, demonstrated less culture senescence and sensitivity to DNA damage, and possessed fewer transmitted reprogramming errors. Luciferase transgene-marked VPs from human embryonic stem cells, CB-iPSCs, and fibroblast-iPSCs were injected systemically or directly into the vitreous of retinal ischemia-reperfusion-injured adult nonobese diabetic-severe combined immunodeficient mice. Only human embryonic stem cell- and CB-iPSC-derived VPs reliably homed and engrafted into injured retinal capillaries, with incorporation into damaged vessels for up to 45 days.

conclusionsVPs generated from CB-iPSCs possessed augmented capacity to home, integrate into, and repair damaged retinal vasculature.

Indexed as

AnimalsCapillariesCellular SenescenceDisease Models, AnimalDNA DamageEmbryonic Stem CellsFetal BloodFibroblastsGraft SurvivalHumansMiceMice, Inbred NODMice, SCIDPluripotent Stem CellsRegenerationReperfusion Injuryblood supplydiabetic retinopathyembryonic stem cellsinduced pluripotent stem cellsreperfusion injurystem cellstransplantation

Identifiers

PMID24163065
PMCPMC4090244
OpenAlexW1980419039

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.